Important news coming from CNETS India about an upcoming single centre prospective trial on Lu 177 PRRT vs Lu 177 PRRT with CapTem chemotherapy in GEP-NETs. Key inclusion criteria for the trial are:
• Well-differentiated GEP-NETs (gastro-entero-pancreatic neuroendocrine tumors)
• All G1 and G2 (Ki-67 of 3-5%) with progressive disease in 6 months
• All G2 and G3 tumors
• Positive Ga-DOTA PET/CT and FDG PET/CT
For more information turn to your medical professional or to the Department of Nuclear Medicine at Tata Memorial Hospital, Mumbai, India.